Development of Chimeric Antigen Receptors Targeting Multiple Myeloma

Division Of Basic Sciences - Nci

Investigators

Linked publications, trials & patents

Abstract

As part of this project, we previously developed an anti-B-cell maturation antigen (BCMA) CAR with an antigen-recognition domain made up of a single human antibody heavy chain variable domain. This CAR, designated FHVH33-CD8BBZ, was highly active in vitro and in mice. We have completed enrollment of patients onto a clinical trial of FHVH33-CD8BBZ-expressing T cells. This trial was successful. the median progression-free survival of patients on the trial was 18 months, and the toxicity profile was acceptable. We conducted a clinical trial with T cells expressing FHVH33-CD8BBZ. We previously completed a clinical trial of an anti-SLAMF7 CAR. This trial was not successful with no patients obtaining prolonged responses, so substantial effort has been expended in laboratory studies to determine why the anti-SLAMF7 CAR T cells did not give the desired clinical results. We have expended extensive time and resources to determine why the anti-SLAMF7 CAR T cells did not function as expected in the clinical trial. This work continues, and we anticipate submitting a manuscript describing it in 2026.